Invivyd Inc. Common Stock Q3 2025 Earnings Recap

IVVD Q3 2025 November 6, 2025

Get alerts when IVVD reports next quarter

Invivyd's Q3 2025 results reflect a pivotal shift towards advancing its COVID prevention efforts, bolstered by significant FDA feedback and a strategic fundraising initiative that provides robust financial support for upcoming clinical programs.

Earnings Per Share Miss

$-0.06 vs $-0.05 est.

-20.0% surprise

Revenue Miss

13129000 vs 15515000 est.

-15.4% surprise

Market Reaction

1-Day +1.32%

5-Day +8.55%

30-Day +64.47%

See IVVD alongside your other holdings

Add to your portfolio — free

Key Takeaways

Invivyd raised approximately $87 million in capital to fund pivotal studies for its vaccine alternative antibody, VYD2311, positioning the company for key developments ahead.
The FDA has provided encouraging feedback to develop VYD2311 for broader populations that are underserved by current COVID vaccines, expanding Invivyd’s market opportunity.
The imminent launch of VYD2311 is supported by anticipated manufacturing capacities and a disciplined approach to operating expenditures.
Upcoming clinical trials aim to deliver top-line results by mid-2026, with a focus on establishing VYD2311's protection efficacy and safety in comparison to existing mRNA vaccines.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit IVVD on AllInvestView.

Next Q1 2026